📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Kopran Receives NSE 'No Objection' for Merger with Kopran Laboratories
Kopran Limited has received a 'No Objection' observation letter from the National Stock Exchange (NSE) on February 27, 2026, regarding its proposed merger with Kopran Laboratories Limited. This follows the initial board approval from March 20, 2025, and allows the company to proceed with filing the scheme before the NCLT. The company is now required to provide detailed disclosures to shareholders, including a 3-year financial track record (Revenue, PAT, EBITDA) and the impact on promoter shareholding. The merger aims to consolidate operations, though the final scheme remains subject to NCLT and other regulatory approvals.
Key Highlights
Received NSE 'No Objection' on February 27, 2026, for the merger of Kopran Laboratories into Kopran Limited.
The observation letter is valid for 6 months, requiring the scheme to be submitted to the NCLT by late August 2026.
Mandatory disclosure of 3-year audited financials (Revenue, PAT, EBITDA) for both entities is required for shareholder approval.
Company must prominently disclose any increase in promoter shareholding and the specific rationale for the swap ratio.
The scheme involves the transfer of all liabilities from the unlisted Transferor Company to the listed Transferee Company.
💼 Action for Investors
Investors should review the upcoming shareholder notice for the specific swap ratio and the impact on promoter equity dilution. Monitor the NCLT approval process as the next major milestone for the consolidation.
Kopran Receives BSE 'No Adverse Observation' for Merger with Kopran Laboratories
Kopran Limited has received a 'no adverse observation' letter from BSE Limited regarding its proposed merger with Kopran Laboratories Limited. This regulatory milestone follows the initial board approval granted on March 20, 2025. The company is now authorized to proceed with filing the scheme before the National Company Law Tribunal (NCLT) within the next six months. The merger remains subject to further approvals from the NCLT, shareholders, and other regulatory bodies.
Key Highlights
BSE issued the 'no adverse observation' letter on February 26, 2026, for the Scheme of Amalgamation.
The merger involves the absorption of Kopran Laboratories Limited (Transferor) into Kopran Limited (Transferee).
The observation letter is valid for six months, during which the company must submit the scheme to the NCLT.
SEBI has mandated detailed disclosures in the shareholder notice, including a cost-benefit analysis and changes in promoter shareholding.
The company must ensure that financial data used for the valuation report is not more than six months old at the time of filing.
💼 Action for Investors
Investors should monitor the upcoming NCLT filing and review the detailed explanatory statement for the swap ratio and potential synergy benefits. The stock may see positive sentiment as the consolidation process moves toward the final legal stages.
Kopran Limited Reports Cyber-attack on Server Data at Khopoli Factory
Kopran Limited has disclosed a cybersecurity incident involving unauthorized access to its computer server data at the Khopoli factory. The breach was identified on February 20, 2026, at approximately 3:50 p.m., prompting immediate restrictive actions by the company. Currently, Kopran is working with external cybersecurity experts to conduct a root cause analysis and assess any potential data or operational impact. While the company has taken steps to secure its systems, the full extent of the breach and its financial implications remain under investigation.
Key Highlights
Unauthorized access to computer server data detected at the Khopoli factory on February 20, 2026
Incident officially reported to the Compliance Officer at 3:50 p.m. on the same day
Immediate measures implemented to restrict further unauthorized access to the company's servers
Cybersecurity experts engaged for a thorough impact assessment and root cause analysis
💼 Action for Investors
Investors should monitor subsequent filings for updates on data recovery and potential operational disruptions. Maintain a cautious stance until the company confirms no sensitive intellectual property or financial data was compromised.
Kopran Q3 Revenue Rises 17% YoY to ₹194 Cr; PAT Dips 10% to ₹9.34 Cr
Kopran Limited reported a 16.8% YoY increase in consolidated revenue from operations to ₹194.28 crore for the quarter ended December 31, 2025. Despite the revenue growth, consolidated net profit declined by 10.1% YoY to ₹9.34 crore, down from ₹10.40 crore in the same quarter last year. On a sequential basis, the company returned to profitability after reporting a net loss of ₹9.92 crore in the previous quarter (Q2 FY26). For the nine-month period, net profit remains significantly lower at ₹6.87 crore compared to ₹28.87 crore in the previous year.
Key Highlights
Consolidated Revenue from Operations grew 16.8% YoY to ₹194.28 crore in Q3 FY26.
Consolidated Net Profit for the quarter stood at ₹9.34 crore, a 10.1% decline from ₹10.40 crore in Q3 FY25.
The company achieved a significant sequential turnaround from a net loss of ₹9.92 crore in Q2 FY26.
Nine-month (9M FY26) consolidated PAT dropped sharply to ₹6.87 crore from ₹28.87 crore in 9M FY25.
Basic EPS for the quarter was ₹1.93, compared to ₹2.16 in the corresponding quarter of the previous year.
💼 Action for Investors
Investors should note the sequential turnaround from a loss in Q2, but remain cautious due to the significant year-on-year decline in nine-month cumulative profitability. Monitor the company's ability to sustain this recovery and manage operating costs in the upcoming quarters.
Kopran Q3 FY26 Net Profit Recovers to ₹9.34 Cr; Revenue Up 17% YoY to ₹194.28 Cr
Kopran Limited reported a strong sequential recovery in Q3 FY26, with revenue reaching ₹194.28 crore, a 64.7% increase over Q2 FY26. Net profit returned to the black at ₹9.34 crore after a loss of ₹9.92 crore in the previous quarter, though it remains slightly lower than the ₹10.40 crore earned in Q3 FY25. EBITDA margins saw a significant rebound to 10.42% from a low of 2.51% in Q2. The company's revenue was well-balanced between its API (₹100.05 crore) and Formulations (₹92.31 crore) segments, with a heavy focus on exports.
Key Highlights
Revenue from operations grew 16.8% YoY to ₹194.28 crore and 64.7% QoQ.
Net Profit stood at ₹9.34 crore, recovering from a net loss of ₹9.92 crore in Q2 FY26.
EBITDA margin improved significantly to 10.42% compared to 2.51% in the preceding quarter.
API segment revenue reached ₹100.05 crore, with exports contributing 67% of the total API sales.
Formulations segment contributed ₹92.31 crore, with Penicillin-based products accounting for 59% of the mix.
💼 Action for Investors
Investors should monitor the sustainability of the margin recovery and the progress of the new API facility at Panoli, Gujarat. The sharp sequential turnaround suggests operational issues from the previous quarter have been addressed.
Kopran Q3 Results: Revenue Grows 17% YoY to ₹194 Cr, PAT at ₹9.3 Cr with Strong QoQ Turnaround
Kopran Limited reported a consolidated revenue of ₹194.28 crore for Q3 FY26, a 16.8% increase compared to ₹166.24 crore in the same quarter last year. The company achieved a significant sequential turnaround, posting a PAT of ₹9.34 crore compared to a loss of ₹9.92 crore in Q2 FY26. However, on a year-on-year basis, PAT declined by approximately 10% from ₹10.40 crore. The nine-month performance remains weak, with cumulative PAT falling to ₹6.87 crore from ₹28.87 crore in the previous year, primarily due to higher expenses and forex losses earlier in the fiscal year.
Key Highlights
Consolidated Revenue from Operations rose 16.8% YoY to ₹19,427.98 Lakhs.
Achieved a sharp QoQ turnaround with a PAT of ₹933.96 Lakhs versus a loss of ₹992.32 Lakhs in the previous quarter.
9M FY26 PAT stands at ₹686.57 Lakhs, a significant drop from ₹2,887.46 Lakhs in 9M FY25.
Foreign Exchange Loss of ₹247.22 Lakhs was recorded in the consolidated results for the quarter.
Consolidated Basic EPS for the quarter stood at ₹1.93 compared to ₹2.16 in the year-ago period.
💼 Action for Investors
Investors should focus on the company's ability to maintain this sequential recovery in margins and revenue. While the QoQ turnaround is positive, the sharp decline in nine-month cumulative profits suggests long-term cost pressures that warrant a cautious approach.
GST Authorities Conduct Search at Kopran's Mumbai and Raigad Facilities
Maharashtra State GST authorities initiated a search at Kopran Limited's registered office in Mumbai and its manufacturing facilities in Khopoli, Raigad on January 21, 2026. The search was conducted under Section 67 of the Maharashtra Goods and Services Tax Act, 2017. While the search is ongoing, the company has stated that normal operations remain unaffected and no specific allegations of violations have been shared by the officials yet. There is currently no quantifiable financial impact reported, but the situation warrants monitoring for potential tax liabilities or penalties.
Key Highlights
Search initiated by Deputy Commissioner of State Tax, SGST (Maharashtra) on January 21, 2026.
Action taken under Section 67 of the Maharashtra Goods and Services Tax Act, 2017.
Locations involved include the Mumbai registered office and Khopoli (Raigad) manufacturing works.
Company reports no impact on normal operations of factories or offices during the search process.
No specific violation details or financial implications have been communicated by authorities as of the announcement.
💼 Action for Investors
Investors should monitor further disclosures regarding the outcome of the GST search to assess any potential tax demands or penalties. Maintain a cautious stance until the company clarifies the nature of the alleged contraventions.
CRISIL Reaffirms Kopran's Ratings at BBB+/A2; Placed on Watch with Developing Implications
CRISIL has reaffirmed the credit ratings for Kopran Limited and its subsidiary, Kopran Research Laboratories Limited, covering total bank facilities of Rs. 194.06 crore. The long-term rating is maintained at CRISIL BBB+ and the short-term rating at CRISIL A2. Notably, the ratings have been placed on 'Rating Watch with Developing Implications,' suggesting potential volatility in the credit profile. This status will remain in effect until March 31, 2026, pending further developments in the company's financial or operational standing.
Key Highlights
CRISIL reaffirmed Long-Term rating at BBB+ and Short-Term rating at A2 for the group.
Kopran Limited's total bank loan facilities rated amount to Rs. 69.31 Crore.
Subsidiary Kopran Research Laboratories Limited's facilities rated at Rs. 124.75 Crore.
All ratings placed on 'Rating Watch with Developing Implications' status.
The current ratings are valid through the period ending March 31, 2026.
💼 Action for Investors
Investors should monitor the company for any corporate announcements or financial shifts that could resolve the 'Developing Implications' status. While the reaffirmation shows current stability, the watch status indicates potential for a rating change in the near future.